#1 Clinical Trials Search in Europe

Tofersen

Tofersen, also known as BIIB067 or QALSODY, is an investigational drug being studied in clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) associated with mutations in the superoxide dismutase 1 (SOD1) gene. These trials aim to evaluate the safety, efficacy, and long-term effects of Tofersen in both symptomatic and presymptomatic individuals with SOD1-ALS.

Table of Contents

What is Tofersen?

Tofersen, also known by its research names BIIB067 and QALSODY, is a promising new drug designed to treat a specific type of Amyotrophic Lateral Sclerosis (ALS). ALS is a severe neurological disease that affects nerve cells in the brain and spinal cord, leading to loss of muscle control[1]. Tofersen is specifically targeted at ALS patients who have a mutation in the superoxide dismutase 1 (SOD1) gene[2].

How Tofersen Works

Tofersen works by targeting the root cause of SOD1-ALS. In patients with this type of ALS, the SOD1 gene produces abnormal proteins that can be toxic to nerve cells. Tofersen is designed to reduce the production of these harmful SOD1 proteins[3]. By lowering the levels of toxic SOD1 proteins, Tofersen aims to slow down or potentially halt the progression of ALS in these patients.

Who Can Benefit from Tofersen?

Tofersen is specifically developed for people with ALS who have a confirmed mutation in the SOD1 gene. This includes:

  • Patients already diagnosed with ALS and confirmed to have an SOD1 mutation[2]
  • Individuals who carry an SOD1 mutation but have not yet developed ALS symptoms (known as presymptomatic carriers)[4]

It’s important to note that SOD1-ALS represents only a small percentage of all ALS cases, typically around 2% of ALS patients.

How is Tofersen Administered?

Tofersen is administered through an intrathecal injection. This means the drug is injected directly into the fluid surrounding the brain and spinal cord[1]. The typical dosing schedule includes:

  • Initial loading doses: Given once every 2 weeks for the first month
  • Maintenance doses: Given once every 4 weeks thereafter

This method of administration allows the drug to reach the central nervous system directly, where it can have the most impact on reducing SOD1 protein levels[5].

Clinical Trials and Research

Tofersen has been studied in several clinical trials:

  1. Phase 1/2/3 Trial (NCT02623699): This study evaluated the safety, effectiveness, and proper dosing of Tofersen in ALS patients with SOD1 mutations[1].
  2. Long-Term Extension Study (NCT03070119): This ongoing study is assessing the long-term safety and effectiveness of Tofersen in patients who participated in earlier trials[3].
  3. Presymptomatic Study (NCT04856982): This trial is investigating whether Tofersen can delay or prevent the onset of ALS symptoms in people who carry SOD1 mutations but haven’t developed ALS yet[4].

These trials have shown promising results, including reductions in SOD1 protein levels and potential slowing of disease progression in some patients.

Safety and Side Effects

Like all medications, Tofersen can cause side effects. Common side effects observed in clinical trials include[1]:

  • Headache
  • Back pain
  • Post-lumbar puncture syndrome (headache, nausea, and dizziness after the injection)
  • Fall
  • Pain in extremity

Most side effects were mild to moderate in severity. However, as with any treatment involving spinal injections, there are risks of more serious complications. Patients should discuss all potential risks and benefits with their healthcare provider.

Future Prospects and Ongoing Research

Research on Tofersen is ongoing, with several exciting developments:

  • Expanded Access Program: This program aims to provide Tofersen to eligible SOD1-ALS patients who cannot participate in clinical trials[2].
  • Presymptomatic Treatment: Studies are investigating whether Tofersen can prevent or delay ALS onset in people with SOD1 mutations who haven’t developed symptoms yet[4].
  • Long-term Effects: Ongoing research is examining the long-term safety and effectiveness of Tofersen[3].

While Tofersen represents a significant step forward in treating SOD1-ALS, it’s important to remember that research is ongoing, and the drug’s long-term effects and benefits are still being studied.

Aspect Details
Drug Name Tofersen (also known as BIIB067 or QALSODY)
Target Condition Amyotrophic Lateral Sclerosis (ALS) associated with SOD1 mutations
Administration Method Intrathecal injection
Trial Phases Phase 1, 2, and 3 studies
Key Objectives Evaluate safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics
Primary Outcomes Changes in ALSFRS-R scores, adverse events, SOD1 protein levels
Secondary Outcomes Slow vital capacity, muscle strength, neurofilament levels, time to death or permanent ventilation
Study Populations Symptomatic ALS patients, presymptomatic SOD1 mutation carriers
Trial Durations Ranging from 24 weeks to several years for long-term follow-up

FAQ

  • What is Tofersen and how is it administered? Tofersen is an investigational drug for treating ALS associated with SOD1 mutations. It is administered as an intrathecal injection, which means it's delivered directly into the fluid surrounding the brain and spinal cord.
  • What are the main objectives of the Tofersen clinical trials? The main objectives include evaluating the safety, tolerability, and efficacy of Tofersen in patients with SOD1-ALS. Trials also aim to assess its pharmacokinetics, pharmacodynamics, and effects on disease progression and biomarkers.
  • Are there any trials for presymptomatic individuals with SOD1 mutations? Yes, there is a trial (NCT04856982) specifically designed for presymptomatic adults with confirmed SOD1 mutations. This study aims to evaluate the efficacy of Tofersen when initiated before the onset of ALS symptoms.
  • What are some of the key outcomes measured in these trials? Key outcomes include changes in ALS Functional Rating Scale-Revised (ALSFRS-R) scores, slow vital capacity (SVC), muscle strength, levels of SOD1 protein and neurofilament light chain in cerebrospinal fluid and plasma, and time to death or permanent ventilation.
  • How long do these clinical trials typically last? The duration of these trials varies. Some studies last up to 24 weeks, while others, particularly those with extension phases, can continue for several years to assess long-term safety and efficacy.

Ongoing Clinical Trials on Tofersen

  • Study of Tofersen for Adults with Presymptomatic Amyotrophic Lateral Sclerosis (ALS) Due to SOD1 Gene Mutation

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Poland Spain Sweden

Glossary

  • Amyotrophic Lateral Sclerosis (ALS): A progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, leading to loss of muscle control.
  • Superoxide Dismutase 1 (SOD1): An enzyme that helps break down potentially harmful oxygen molecules in cells. Mutations in the SOD1 gene are associated with some cases of ALS.
  • Intrathecal injection: A method of delivering medication directly into the fluid surrounding the brain and spinal cord.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and relationship between drug concentration and effect.
  • Neurofilament Light Chain (NfL): A protein released into cerebrospinal fluid and blood when neurons are damaged, used as a biomarker in neurological diseases.
  • ALS Functional Rating Scale-Revised (ALSFRS-R): A questionnaire-based scale used to measure the functional status of ALS patients, assessing areas such as speech, salivation, swallowing, and breathing.
  • Slow Vital Capacity (SVC): A measure of lung function, specifically the amount of air that can be slowly exhaled from the lungs after taking a deep breath.
  • Cerebrospinal Fluid (CSF): The clear, colorless fluid that surrounds the brain and spinal cord, protecting them from injury and providing nutrients.
  • Handheld Dynamometry (HHD): A method used to measure muscle strength using a handheld device that quantifies the force produced by specific muscle groups.

References

  1. https://clinicaltrials.gov/study/NCT02623699
  2. https://clinicaltrials.gov/study/NCT04972487
  3. https://clinicaltrials.gov/study/NCT03070119
  4. https://clinicaltrials.eu/trial/study-of-tofersen-for-adults-with-presymptomatic-amyotrophic-lateral-sclerosis-als-due-to-sod1-gene-mutation/
  5. https://clinicaltrials.gov/study/NCT03764488